Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
propyl nicotinate
- Development stage
- Phase 3
- Lead developer
- Esteve
- Modality
- Small Molecules
- Administration
- Topical
01
Overview
Elacur Hot is a topical vasodilator cream containing **propyl nicotinate** (2.0%) as its active ingredient. Developed and marketed by **RIEMSER**, it is indicated for the relief of muscle tension and pain associated with conditions such as myalgias, neuralgias, and rheumatic complaints. Upon topical application, propyl nicotinate acts as a vasodilator, increasing local blood flow and generating a warming effect in the treated area. The product has been specifically investigated in a double-blind, randomized, placebo-controlled Phase III clinical trial in Germany as an adjuvant treatment for chronic non-specific low back pain. It is intended for use in adults and children over 12 years of age.
- Brand names
- Elacur Hot
- Other names
- propylnicotinat
02
Targets
HCAR2 (Hydroxycarboxylic acid receptor 2)
Beyond the preview
Go deeper on propyl nicotinate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on propyl nicotinate.